Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)
November 17, 2022 11:02 AM EST
R&D

Cure­Vac puts lead on­col­o­gy can­di­date on back burn­er and will on­ly move it for­ward in com­bi­na­tion ther­a­pies

Paul Schloesser

Associate Editor

Cure­Vac is putting its lead can­cer ther­a­py on ice — for now.

The trans-at­lantic phar­ma with of­fices in Boston, MA and Ger­many put word of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times